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A COVID related fraud at Applied BioSciences Corp.: What are the Lessons?

ABSTRACT
This case is based on fraudulent COVID-related press releases by Applied BioSciences Corp.
(APPB) in a “pump-and-dump” scheme, and the related SEC complaints. In this case study,
students assume the role of an external auditor and become familiar with several auditing and
intermediate accounting concepts, including: fraud, ethical reasoning and utilitarian principles,
fraud red flags and fraud risk assessment, accounting for goodwill, accounting for intangibles, SEC
investigations, and regulation. Students at an accredited Midwestern University participated in this
case. We provide assessment information and implementation suggestions to interested instructors.
Student feedback was positive about the learning outcomes of this case.
Keywords: COVID-19 fraud; fraud risk factors; ethical reasoning; utilitarian ethics; accounting
for intangibles; horizontal and vertical analyses
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Case Introduction
On May 14th, 2020, the Security and Exchange Commission (SEC) announced charges
against Applied BioSciences for making false statements about offering and shipping coronavirus
test kits to the general public to combat the spread of COVID-19 (SEC v. Applied BioSciences
Corp, 2020). As news of the COVID-19 outbreak dominated headlines throughout the globe,
Applied BioSciences issued press releases to announce that it was shifting its manufacturing
resources from development of synthetic cannabinoid therapeutics/biopharmaceuticals to the
manufacturing of products that would help battle the spread of COVID-19. On March 25th, 2020,
the company first announced it would create and sell through an affiliate a new hand sanitizer
(Applied BioSciences Corp. 2020a) and then, on March 31st, 2020, the company announced it
began shipping Coronavirus Test Kits to the general public for private use (Applied BioSciences
Corp., 2020b).
As a result of these press releases, Applied BioSciences’ stock price and trading volumes
increased significantly. As a result of the March 31st press release, Applied BioSciences stock price
increased from $.45 per share to $.80 per share and the share volume increased from 1,600 on
March 30, 2020, to a volume 136,300 on the date of the release (See Figure 1). On April 13, 2020,
the SEC suspended the trading of the company’s stock for 10 days because questions arose
concerning the accuracy of Applied BioSciences public statements and the company’s ability to
distribute tests where the technology had not been approved by the FDA for home use (SEC
2020c). In an April 24th press release, Applied BioSciences announced that it had terminated its
agreement with its supplier for COVID-19 test kits and said that it had not distributed, and would
not be distributing, test kits (Applied BioSciences Corp. 2020c). The company also defended its
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March 31st press release, stating that at the time of the release, the FDA did not disallow the use
of the test kit for home use without the administration of the test by a qualified medical
professional, but that by April 1st, the FDA had notified the test kit supplier that home use was not
allowed.
In its complaint, the SEC alleged that Applied BioSciences misled the public by stating
that it was diverting manufacturing resources when in fact it did not, by claiming it had “begun
shipping” the COVID-19 home test kits when in fact it did not, and by failing to disclose that the
FDA had not approved a COVID-19 test kit for home use at the time of the public disclosure (SEC
v. Applied BioSciences Corp, 2020). The complaint alleged that Applied BioSciences knew or was
reckless in knowing that the test kits were subject to FDA review and that no test kit for home use
had been approved by the FDA at that time. The materially misleading nature of these press
releases suggests that Applied BioSciences was seeking to exploit the COVID-19 pandemic for
profit.
Company Overview
From its inception, Applied BioSciences had trouble trying to figure out its business model.
The company was co-founded by Colin Povall and Scott Stevens in 2014 as First Fixtures, Inc.
with the intention to become an online shopping mall specializing in the sale of bathroom and
kitchen fixtures and faucets. A little over two years later, the company completed a reverse merger
with Stony Hill Ventures, changed its name to Stony Hill and started to develop and sell cannabis
therapeutics. Soon after, the company amended its articles of incorporation again to change its
name to Applied BioSciences Corporation.
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The cannabis industry presented some challenges to the company. Currently, the use, sale,
and possession of cannabis products are illegal under U.S. federal law (16 USC § 559b). From a
federal tax perspective, Applied BioSciences is prohibited from deducting any expenditures related
its cannabis products on the company’s income tax return under the I.R.C. tax code (26 USC §
280E). Additionally, most big banks still refuse to work with cannabis companies because banks
are required to file reports to the federal government detailing a customer’s suspicious or illegal
activities. Since marijuana is still illegal at the federal level, banks are required to file these reports.
This compliance can be costly to banks. Also, almost half of Applied Biosciences’ working assets
come from accounts receivable suggesting that cannabis customers are not as reliable in paying
their bills. Finally, mounting losses and an auditor’s opinion that expressed doubts about the
company’s ability to continue as a going concern weighed on Applied BioSciences.
Fraud
An opportunity to reinvent itself came to Applied BioSciences with the beginning of the
COVID-19 pandemic. The company decided to shift its focus from cannabinoid-based products to
pandemic-related products, when it announced on March 25, 2020, that the company was
dedicating resources to build products that would help battle the spread of COVID-19, including
hand sanitizer (Applied BioSciences Corp. 2020a). This announcement came as a surprise to the
market and created confusion among some investors. Upon Applied BioSciences announcement,
one investor wrote in the company’s Yahoo! conversations form, “The Coronavirus has caused
major stores run out of Hand Sanitizers, So $APPB stock recently launched a CBD hand sanitizer
product line. Price move in the range of $1.95 to $2.10 anticipated with $APPB shares”. Another
commentator inaccurately stated, “$APPB mj stock selling and shipping CBD infused Hand
5

Sanitizers” (Yahoo! Finance, 2020). One week later, the company announced it had begun
shipping Coronavirus Test Kits to the general public for private use (Applied BioSciences Corp.
2020b). Figure 1 illustrates the closing stock price and trading volume for APPB for the period in
question and highlights the increased stock trading activity surrounding the announcements. On
March 31, 2020 (day of first press release), APPB’s stock price increased almost 80 percent from
the previous day (from $0.45 to $0.80), and its volume increased 85 times (136,300 shares sold,
versus 1600 shares sold on the previous day).

[INSERT FIGURE 1 HERE]

Around this same time, the SEC's Division of Enforcement had formed a Coronavirus
Steering Committee to coordinate and oversee the Division's response to COVID-19 related
misconduct (SEC 2020a, 2020c). The creation of this committee was a result of the lessons the
SEC learned from previous public health crises and emergencies such as Hurricane Katrina in
2005 and the Ebola crisis of 2014 where some publicly traded companies would make fraudulent
claims of treatments or disaster-response capabilities that were designed to unfairly profit from
these events. As a result of the Committee’s efforts, there was a surge of disclosure-related
enforcement actions at the beginning of the pandemic mostly directed towards micro-cap
companies like Applied BioSciences. These enforcement actions sent the message to publicly
traded companies that the SEC intended to respond to COVID-related matters swiftly to protect
investors.
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Ultimately, the U. S. District Court for the Southern District of New York entered a final
judgment against Applied BioSciences with respect to the company’s misleading claims (SEC v.
Applied BioSciences Corp, 2020). While Applied BioSciences did not admit to or deny the
allegations of the SEC, the company consented to the entry of a final judgment restraining it from
future violations of Section 10(b) of the Securities Exchange Act of 1934 and paid a $25,000 civil
penalty (SEC 2020d).
Aside from the federal action by the SEC, Applied BioSciences also faced state and local
enforcement actions. For example, the city and county district attorneys of Los Angeles, CA jointly
brought an action against Applied BioSciences for “unlawfully advertising and selling an in-home
COVID-19 antibody blood test that has not been approved by the Food and Drug Administration
(FDA)” (People of the State of California v. Applied BioSciences Corp., 2020; Feuer, 2020).
Similar to the SEC, these local law enforcement entities made efforts to discourage COVID-19
related scams from the beginning of the pandemic. For the city and county of Los Angeles, they
started a campaign to protect their local citizens from these scams. As opposed to the SEC’s
motivation to primarily protect investors, these local efforts seemed to focus more on protecting
the health and safety of the local population. For example, L.A. district attorney George Gascon
highlighted the importance of public health in his comments about the action against Applied
BioSciences. He said, "the harm is not only financial, but also potentially deadly. Victims, who
received false negative test results, may fail to seek treatment and fail to quarantine, contributing
to the spread of the disease. Meanwhile, those with false positive test results may seek unnecessary
treatment, burdening our already strained healthcare system" (Feuer, 2020). Applied BioSciences
settled with the city and county of Los Angeles by complying with an injunction prohibiting the
7

sale of unapproved tests, paying full restitution to those who purchased the test and paying a
$50,000 civil penalty (Feuer, 2021).
Aftermath
As a result of the enforcement actions, APPB’s normal business operations appear to
have slowed down, although the company website is still functioning. As of September 2022,
when this case was written, the company’s stock price was valued at $0.0025 per share. APPB
has not issued any public press releases since April 2020 when it corrected its fraudulent
COVID-related press releases.
Case Questions
Please study the case carefully. You may also review Income Statements and Balance Sheets of
Applied BioSciences Corp. Bullet point (complete sentences) answers are ok. You may review
the SEC complaint also.
(1) Who were all affected by the fake COVID-19 press releases by Applied BioSciences
Corp. (APPB)? How were they affected? Please read about “Utilitarianism” in your
auditing text –[Answer in a table format is fine.] “How” column should be short
sentences.
(2) Please review the Income Statements and Balance Sheets for 2018 and 2019 for APPB
at the end of this case. Perform multiple analytical procedures (key ratio analysis) on
Income Statement and Balance Sheet numbers for 2019 and 2018. What conclusions
can you draw from each of the analytical procedure?
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(3) Describe various fraud red flags (under three categories: incentives, opportunities and
rationalization) that are present in this Applied BioSciences Corp. case study. Detailed
bullet point (should be complete sentences) are fine.
(4) Perform a horizontal analysis on the Balance Sheet and Income Statement data
comparing the years 2018-2019. This is best done in Excel, with two columns, one
listing the dollar amount of change between the two years for a single account, and one
listing the percentage difference of that change over the first-year amount. Which
accounts stand out to you?
(5) In general, when is goodwill recognized? How did Applied BioSciences compute
goodwill? What amounts went into that computation? Comment on the acquisition of
Trace Analytics. What accounts are impacted by this acquisition? Was the acquisition
in the best interest of the company? You may reference the section in chapter 12 on
goodwill for help answering the first part of this question.
(6) Calculate the gross profit margin percentage relating to “product” for 2018. Use that
percentage to estimate the product cost of revenue and product gross profit margin for
2019. Compare that estimate to the actual product gross profit margin percentage for
2019. How does Applied BioSciences explain this discrepancy?
(7) Explain what is driving the $2.1M G&A expense in 2019, and whether the increase
over 2018 is appropriate (HINT: as part of your discussion, consider the nature of fixed
versus variable costs). How does Applied BioSciences explain this increase? How is
your assessment of this account impacted by the knowledge of the fraud perpetrated by
Applied BioSciences (see the SEC complaint and SEC resolution)?
9
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CASE LEARNING OBJECTIVES AND IMPLEMENTATION GUIDANCE
The authors developed an instructional case based on an actual event that occurred at
Applied BioSciences Corp. We did not add any fictitious information to improve the learning
objectives. Instructional cases offer students an opportunity to apply accounting rules and to
develop judgement in courses such as intermediate accounting and auditing. Developing these
skills are important to accounting majors to perform well in their entry-level jobs. This case
permits accounting students to study the details of a fraud that occurred at a publicly traded
company during the early stages of the COVID pandemic.

Learning Objectives
This case can be used in auditing and intermediate accounting classes. This instructional
tool was developed to increase students’ skills in analysis, interpretation, and evaluation of realworld financial data.
The specific learning objectives for this case project are as follows:
•

Apply Utilitarian ethical reasoning

•

Understand accounting for goodwill

•

Understand accounting for intangibles

•

Evaluate fraud risk factors (AU 316)

•

Design analytical procedures

•

Perform vertical and horizontal analyses on real company data

•

Governance in a publicly traded company

•

Going concern evaluation
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Implementation Suggestions
This case was used in undergraduate in auditing and an intermediate accounting classes. It
is recommended that students be familiar with the following topics prior to completing the case:
fraud, Code of Professional Ethics, generally accepted auditing standards, professional
skepticism, goodwill accounting, and accounting for intangible assets. All seven questions were
not assigned in any one class. Intermediate students were assigned questions 4, 5, 6 and 7, whereas
auditing students were assigned other questions, namely 1, 2 and 3.
The case was presented to students via an email. The instructor selected group members
randomly and this method of group selection matches the work environment. Student groups of
3 members per group seemed to offer participation opportunity to everyone. Students were
required to read the case and answer questions through discussion with their group members
outside of class time. Students were allowed ten days to two weeks to work through the case
questions and submit their group answer to the instructor.

Assessment of Student Learning
This case was assigned during the Fall and Spring of 2021 to students in auditing and
during the Fall of 2021 to intermediate accounting students. Only two to three questions were
used at a time. Students had a good understanding of the case and the majority of participants
provided responses that were consistent with the solution. Auditing students applied the
Utilitarian ethical principles and came up with several groups/parties that were affected by this
fraud and explained how they could be affected. Auditing students completed this case in groups
outside of class and were able to perform several analytical (ratio comparisons) procedures and
make useful inferences. They were also diligent in identifying fraud risk factors under three
13

categories: incentives, opportunities and rationalization. Intermediate accounting students were
able to accurately perform a horizontal analysis on Applied BioSciences’ financial statements
and perform ratio analyses to identify potential red flags. Additionally, they were able to
accurately define goodwill and critically analyze Applied BioScience’s acquisition of Trace
Analytics. In general, intermediate accounting students were able to analyze the consolidated
financial statements and provide well-reasoned financial analysis of the company in light of the
SEC complaint.
Additional Case Assessment
As the focus of the questions differed slightly for the two groups of students, we discuss
their perceptions and feedback separately. Table 3 summarizes students’ perceptions and feedback
to the case. Table 4 lists a sample of student comments about the case. Table 3 indicates that
auditing students responded, in general, favorably to the use of the case as a class assignment in
the auditing class. A big majority of students either agreed or strongly agreed that completing the
case helped them better understand the following concepts: red flags related to fraud, ethical
reasoning, horizontal and vertical analysis (analytical procedures), and AU 316 (AICPA). A high
percentage of students judged the level of difficulty associated with the case to be appropriate for
a senior-level auditing course. Students were strongly in agreement that doing this case as a group
project was beneficial. A large majority of students were of the opinion that this case was a useful
learning tool.
Table 3 also summarizes intermediate accounting students’ perceptions and feedback to
the case. Similar to auditing students, intermediate accounting students also responded favorably
to the use of the case as a class assignment in the intermediate accounting class. A large majority
14

of students either agreed or strongly agreed that completing the case helped them better understand
the following concepts: acquisitions and goodwill computation, horizontal and vertical analysis
(analytical procedures), the use of note disclosures in financial statements. A high percentage of
these students judged the level of difficulty associated with the case to be appropriate for an
intermediate-level accounting course. Some intermediate accounting students were appreciative
that this was a group case, while others felt that this case could be better handled as an individual
assignment. A large majority of students viewed this case as a useful learning tool. Table 4 lists a
small sample of student comments about the case.

[INSERT TABLES 3 AND 4 HERE]

CONCLUSION
Undergraduate auditing and intermediate accounting students participated in solving this
case. Given the pervasive impact of the COVID-19 pandemic, students felt a certain level of
personal connection with the assignment, compared to other fraud cases. Because it is based on a
COVID fraud that occurred at a publicly traded micro-cap company students had access to material
on the financial press and were motivated to analyze this case. Students enhanced their critical
thinking and professional judgment, by developing detailed group answers for several key
questions on ethical reasoning, identification of fraud risk factors (AU 316), horizontal and vertical
analyses, analytical procedures, accounting for goodwill and intangible assets. The case was
analyzed by students working in teams and as such developed useful interpersonal skills as well.
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Figure 1. Applied BioSciences Corp. (APPB) Stock Performance
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Table 1. Balance Sheet
CONSOLIDATED BALANCE SHEETS - USD ($)

Mar. 31, 2019

Mar. 31, 2018

$47,044
163,405
78,737
65,273
354,459
452,048
898,292
1,941,149
5,500
3,651,448

$60,934
12,386
29,074
124,455
226,849
4,441
468,537

278,546
25,000
70,720
374,266

21,846

135

105

6,892,242

3,054,297

Common stock to be issued, 408,805 and 263,000 shares at March 31, 2019 and
2018, respectively
Accumulated deficit

773,807
-5,531,260

526,000
-2,901,933

Total Applied BioSciences Corp. Stockholders' Equity
Non-controlling interest
Total Stockholders' Equity
TOTAL LIABILITIES & STOCKHOLDERS' EQUITY

2,134,924
1,142,258
3,277,182
$3,651,448

678,469
-9,027
669,442
$705,327

Current Assets
Cash
Accounts receivable, net
Inventory
Prepaids and other current assets
Total Current Assets
Property and equipment, net
Equity investments
Goodwill
Other asset
TOTAL ASSETS
Current Liabilities
Accounts payable
Note Payable
Accrued expenses
Total Current Liabilities
Commitments and Contingencies
Stockholders' Equity

5,500
705,327

14,039
35,885

Preferred stock; $0.00001 par value; 5,000,000 shares authorized; none issued
and outstanding at March 31, 2019 and 2018
Common stock; $0.00001 par value; 200,000,000 shares authorized; 13,397,110
and 10,499,610 issued and outstanding at March 31, 2019 and 2018,
respectively
Additional paid in capital
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Table 2. Income Statement
CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)
12 Months Ended
REVENUE, NET
Products
Services
Total revenues, net
COST OF REVENUE
Products
Services
Total costs of revenue
GROSS MARGIN
EXPENSES
Sales and marketing
General and administrative
Depreciation and Amortization
Impairment of asset
TOTAL OPERATING EXPENSES
OPERATING LOSS
Other Income (Expense)
Change in fair value of equity investments
Dividend received from equity investment
Interest Expense
Total other (expense), net
NET LOSS
Less: Net loss (income) attributable to non-controlling interest
NET LOSS ATTRIBUTABLE TO APPLIED BIOSCIENCES CORP.
LOSS PER COMMON SHARE
WEIGHTED AVERAGE SHARES OUTSTANDING
Basic and diluted
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Mar. 31, 2019

Mar. 31, 2018

$543,970
163,092
707,062

$197,554

498,993
22,781
521,774
185,288

155,549

698,185
2,092,775
40,627

356,948
953,484
224,770
893,667

2,831,587
-2,646,299

2,428,869
-2,386,864

429,755
186,397
-648,875
-32,723
-2,679,022
49,695
($2,629,327)
($0.22)

-2,386,864
10,763
($2,376,101)
($0.16)

11,914,525

15,071,417

197,554

155,549
42,005

Table 3: Evaluation for the Applied BioSciences (APPB) Case
We ask participants to specify their agreement with the following statements, where 1 =
“Strongly Agree”, 2 = “Agree”, 3 = “Neutral”, 4 = “Disagree”, and 5 = “Strongly Disagree”
Item
1. Completing the APPB case helped me understand ethical
issues in general.
2. Completing the APPB case helped me understand how several
groups can be affected by unethical acts.
3. Completing the APPB case helped me understand how
goodwill is computed and reported in a real-world setting.
4. Completing the APPB case helped me understand how to
assess and critically evaluate a recent acquisition and related
goodwill.
5. Completing the APPB case helped me understand how to do
analytical procedures – horizontal analysis
6. Completing the APPB case helped me understand how to do
analytical procedures – vertical analysis
7. Completing the APPB case helped me understand how fraud
triangle can be applied to a MicroCap company.
8. Completing the APPB case helped me understand fraud risk
factors (red flags) that are related to management attitudes and
rationalizations
9. Completing the APPB case helped me understand how to
navigate the notes to the financial statements.
10. Completing the APPB case helped me understand how the
notes to the financial statements can be used to evaluate
management’s assertions in the balance sheet and the income
statement.
11. The level of difficulty in this case was appropriate for an
upper-level accounting course.
12. The level of difficulty in this case was appropriate for an
intermediate level accounting course.
13. Analyzing this case as a group project was beneficial.
14. Overall, this case was a useful learning tool.
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Auditing
Mean (SD)
1.71 (0.62)

Int Acc
Mean (SD)
NA

1.62 (0.64)

NA

NA

1.90 (0.54)

NA

1.90 (0.54)

1.62 (0.82)

1.40 (0.49)

1.62 (0.82)

1.80 (0.60)

1.5 (0.72

NA

1.54 (0.66)

NA

NA

1.70 (0.90)

NA

1.60 (0.66)

1.66 (0.87)

NA

NA

2.00 (0.89)

1.58 (0.77)

2.30 (0.78)

1.50 (0.66)

1.70 (0.64)

Table 4. Student Feedback
Listed below is a sample of student comments about the case:
Auditing Students

Intermediate Accounting Students
“I think the use of the real-world situations is a
great way to get students who are going into

“I had fun and learned a lot.”

accounting as their major to fully understand
what it is that they are learning and why it is
critical to understand it.”

“The case was a very helpful learning tool that

“I think it was interesting and beneficial for the

helped apply material from class to real-world

most part.”

situations.”

“Let us pick our own groups, if possible.”

“It is a good group project; some parts could
have been independent assignments.”

“It was a bit hard to follow overall in my opinion.
I did the best I could for the time I had available.”
“Good project for navigating and evaluating
financial notes in conjunction with performing the
financial analysis.”

“Overall, I liked the case studies and they helped
me apply the material we were learning in class.”
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